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way to analyze our data would have been to pool all the data
obtained with the two different LMWHs; major chemical, bio-
logical and clinical differences exist between these LMWHs, and
there has been much debate on this issue. We believe that pooling
these data would have generated many more letters to the editor!
There are few biological markers of prognosis in unstable
angina. Our recent studies have focused attention on vWf as a new
marker of potential interest in acute coronary syndromes. It
appeared consistently as a predictive factor of outcome, and we
believe it deserves attention and further evaluation in large studies.
Our most recent publication demonstrated that the new antico-
agulants tested in unstable angina behave better than UH with
regards to vWf release. We agree it should also be confirmed.
Step-by-step we are progressing in the understanding of the role of
vWf in the prognosis of unstable angina, and the time has come for
head-to-head comparisons between the new anticoagulant treat-
ments. In that regard, the ARMADA study has now been
completed and we will share the data very soon. I am sure that Dr.
Ho¨dl will appreciate the results.
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Enoxaparin for Acute Coronary Syndromes?
Goodman et al. (1) conclude that enoxaparin is a more effective
antithrombotic treatment than unfractionated heparin (UFH) for
the prevention of rebound ischemia in patients with unstable
angina or non-Q-wave myocardial infarction. We suggest an
alternative conclusion.
Enoxaparin’s plasma half-life is two to four times longer as
compared to UFH after subcutaneous administration (2), even
more when compared to UFH given intravenously, as in the
Goodman et al. study. Activity against factor Xa and thrombin
disappears only after more than 16 h (3), following moderate doses
of enoxaparin. With high doses, as used in the ESSENCE study
(1), enoxaparin’s plasma half-life is substantially longer (4).
Therefore, after stopping study drugs in the ESSENCE study,
enoxaparin’s antithrombotic effect very likely lasted much longer
than that of UFH. After stopping UFH, ischemic events during
the 48-h monitoring period were twice as frequent as after
stopping enoxaparin (45% vs. 26%), whereas there was no differ-
ence while on active treatment (25%)—compatible with an anti-
thrombotic effect lasting about one day longer after enoxaparin. In
addition, enoxaparin’s antithrombotic effect wanes much more
slowly as compared to IV UFH. This may have added benefit by
attenuating a heparin rebound effect.
It remains to be convincingly shown whether enoxaparin or
other low-molecular-weight heparins exert superior antithrom-
botic effects as compared to UFH. Superior clinical benefit might
be explained by pharmacokinetic differences only. For patients
with acute coronary syndromes, extending the duration and slower
weaning (5) of IV UFH may well be better and cheaper.
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REPLY
Pechlaner et al. suggest that our findings (1) of less rebound
ischemia with enoxaparin as compared to unfractionated heparin
(UFH) are simply due to the longer half-life of enoxaparin.
However, the ischemic episodes (average number and duration)
identified during continuous electrocardiographic monitoring were
statistically significantly lower in the enoxaparin as compared to
the UFH group not only during the first 12 h after drug
discontinuation but also during the .12 to 24-h and even the .36
to 48-h time intervals. This suggests that the benefit seen with
enoxaparin is not simply due to prolonged half-life and greater
anti-Xa:IIa activity that “wanes” more slowly than UFH. Indeed,
there is growing evidence supporting additional mechanisms of
benefit of enoxaparin over UFH beyond the differences in phar-
macokinetics; for example, the significant blunting of the rise of
von Willebrand factor with enoxaparin in the first 48 h of
treatment (2).
As we noted, our substudy (1) was stopped at the time of overall
trial completion but prior to enrollment of an adequately powered
sample size to confidently address the initial 48-h period of active
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